Comparisons & Q&A
Head-to-head comparisons, Q&A explainers, and illustrative patient accounts.
33 articlesGonadorelin vs. Leuprolide: Comparing Pulsatile GnRH Therapy to GnRH Agonist Suppression
Gonadorelin and leuprolide are both built on GnRH, but used correctly they produce opposite effects on the body's hormone axis. Here's the side-by-side.
Read the guide → ⚖️ Comparisons & Q&AGLP-1 Drugs vs. SARMs: Why They Get Confused and Why Their Regulatory Status Isn't Remotely Similar
GLP-1 medications and SARMs both show up in online peptide and biohacking content, but they're chemically unrelated and sit in very different regulatory categories. Here's the actual comparison.
Read the guide → ⚖️ Comparisons & Q&AEcnoglutide vs. Mazdutide: Comparing China's Two Approved Next-Generation GLP-1 Drugs
Ecnoglutide and mazdutide are both approved in China for weight management but work differently. Here's how their mechanisms, trial data, and company backing compare.
Read the guide → ⚖️ Comparisons & Q&APlecanatide vs. Linaclotide: Comparing Two FDA-Approved Peptides for Chronic Constipation
How plecanatide (Trulance) and linaclotide (Linzess), two FDA-approved guanylate cyclase-C agonist peptides, compare on mechanism, approved uses, trial results, and side effects.
Read the guide → ⚖️ Comparisons & Q&AAmycretin vs. Retatrutide: Comparing Two Next-Generation Obesity Drug Candidates
Novo Nordisk's amycretin and Eli Lilly's retatrutide both aim to beat first-generation GLP-1 drugs on weight loss, but through different receptor combinations and at different stages of development. Here's how they compare.
Read the guide → ⚖️ Comparisons & Q&AOctreotide vs. Lanreotide vs. Pasireotide: Comparing the Three FDA-Approved Somatostatin Analogs
All three are FDA-approved somatostatin analogs used for acromegaly and neuroendocrine tumors, but they differ in receptor targeting, dosing schedule, and side-effect profile. Here's how they compare.
Read the guide → ⚖️ Comparisons & Q&ASemaglutide vs. Liraglutide: Comparing First- and Second-Generation GLP-1 Drugs
A head-to-head trial found semaglutide produced more than double the weight loss of liraglutide, with fewer people stopping treatment due to side effects. Here’s what separates the two drugs.
Read the guide → ⚖️ Comparisons & Q&AGlucagon vs. GLP-1: Two Hormones With Opposite Effects on Blood Sugar
One hormone raises blood sugar, the other lowers it, yet the newest obesity drugs deliberately combine both. Here's how that works.
Read the guide → ⚖️ Comparisons & Q&AMariTide vs. Retatrutide: Comparing Two Next-Generation Weight-Loss Candidates
Amgen's monthly MariTide and Eli Lilly's weekly retatrutide take different approaches to the same receptors. Here's how their mechanisms, trial results, and timelines compare.
Read the guide → ⚖️ Comparisons & Q&ATeriparatide vs. Abaloparatide: Comparing Two FDA-Approved Bone-Building Peptides
How teriparatide (Forteo) and abaloparatide (Tymlos), the two FDA-approved anabolic peptide drugs for osteoporosis, compare in mechanism, trial data, and regulatory history.
Read the guide → ⚖️ Comparisons & Q&APemvidutide vs. Survodutide: Comparing Two Glucagon/GLP-1 Dual Agonists in Development
Both pemvidutide and survodutide combine glucagon and GLP-1 receptor activation, but they come from different companies, target different lead indications, and are at different stages of development.
Read the guide → ⚖️ Comparisons & Q&ASurvodutide vs. Mazdutide: Comparing Two GLP-1/Glucagon Dual Agonists in Development
Survodutide and mazdutide both combine GLP-1 with glucagon receptor activity, but they come from different companies and sit at very different regulatory stages. Here's how they compare.
Read the guide → ⚖️ Comparisons & Q&AAwiqli vs. Onswik: Comparing the Two Once-Weekly Basal Insulins
How Novo Nordisk's Awiqli and Eli Lilly's newly approved Onswik compare as once-weekly basal insulin options.
Read more → ⚖️ Comparisons & Q&AGLP-1 Drugs vs. Bariatric Surgery: How the Two Weight-Loss Approaches Compare
A side-by-side look at how GLP-1 medications and bariatric surgery compare on weight loss outcomes, durability, risks, and who each approach is typically appropriate for.
Read the guide → ⚖️ Comparisons & Q&AUBT251 vs. Retatrutide vs. CagriSema: Comparing the Next Wave of Multi-Agonist Obesity Drugs
How three investigational multi-agonist peptides, UBT251, retatrutide, and CagriSema, compare in mechanism, trial results, and development stage.
Read the guide → ⚖️ Comparisons & Q&AVK2735 vs. Retatrutide: Comparing Two Next-Generation Multi-Agonist Peptides in Development
How Viking Therapeutics' VK2735 and Eli Lilly's retatrutide compare on mechanism, trial stage, and available data, and why neither is FDA-approved yet.
Read the guide → ⚖️ Comparisons & Q&ACagriSema vs. Tirzepatide: Comparing Two Approaches to GLP-1-Based Weight Loss
Novo Nordisk's CagriSema and Eli Lilly's tirzepatide take different pharmacological approaches to weight loss. Here's what head-to-head trial data shows.
Read the guide → ⚖️ Comparisons & Q&ARetatrutide vs. Tirzepatide: Comparing the Two Leading Multi-Agonist Weight-Loss Peptides
Tirzepatide is FDA-approved and available today; retatrutide is a still-investigational triple agonist reporting larger trial weight-loss numbers.
Read the guide → ⚖️ Comparisons & Q&AOral Wegovy vs. Rybelsus vs. Injectable Wegovy: Comparing Novo Nordisk’s Semaglutide Options
Same active ingredient, three different products: how oral Wegovy, Rybelsus, and injectable Wegovy differ in dose, approval, and administration.
Read the guide → ⚖️ Comparisons & Q&AOral vs. Injectable GLP-1 Drugs: What Orforglipron Has to Overcome
Why most GLP-1 drugs are injectable peptides, how oral semaglutide works around that limitation, and why orforglipron's non-peptide chemistry sidesteps the problem entirely.
Read the guide → ⚖️ Comparisons & Q&AA Pharmacist Explains How Compounded Peptides Are Made (Q&A Format)
A Q&A-style explainer covering how a compounding pharmacist would describe the process of preparing a compounded peptide medication.
Read the guide → ⚖️ Comparisons & Q&AA Sports Medicine Physician on Peptides in Recovery Protocols (Q&A Format)
A Q&A-style explainer covering how a sports medicine physician would evaluate recovery-focused peptides like BPC-157 and TB-500.
Read the guide → ⚖️ Comparisons & Q&AAn Endocrinologist's Perspective on GLP-1 Peptides (Q&A Format)
A Q&A-style explainer covering common questions an endocrinologist would address about GLP-1 peptide therapy.
Read the guide → ⚖️ Comparisons & Q&ABPC-157 vs. TB-500: Comparing the Evidence for Injury Recovery
How BPC-157 and TB-500 compare in mechanism, marketed uses, and the actual strength of evidence behind each.
Read the guide → ⚖️ Comparisons & Q&ACompounded vs. Brand-Name GLP-1s: What's the Real Difference?
A direct comparison of compounded and brand-name GLP-1 medications: what's actually the same, and what genuinely differs.
Read the guide → ⚖️ Comparisons & Q&AIpamorelin vs. GHRP-6: Comparing Selectivity and Side Effects
Comparing ipamorelin and GHRP-6: receptor selectivity, documented side effects, and what the differences mean in practice.
Read the guide → ⚖️ Comparisons & Q&AOne Patient's Recovery Peptide Experience: An Anecdotal Account With Context
An illustrative, composite account of using a research-chemical recovery peptide, framed against the actual evidence gaps involved.
Read the guide → ⚖️ Comparisons & Q&AOne Patient's Semaglutide Experience: An Anecdotal Account With Context
An illustrative, composite account of a semaglutide treatment experience, framed alongside the clinical trial data it should be read against.
Read the guide → ⚖️ Comparisons & Q&APeptide Therapy vs. Traditional Approaches: A Side-by-Side Look
How peptide therapies compare to traditional medical and lifestyle approaches for weight management and recovery, evidence to evidence.
Read the guide → ⚖️ Comparisons & Q&ASermorelin vs. CJC-1295: Comparing Growth Hormone Peptide Therapies
Comparing sermorelin and CJC-1295, two growth hormone releasing hormone analogs with different regulatory histories.
Read the guide → ⚖️ Comparisons & Q&ATirzepatide vs. Semaglutide: Comparing Efficacy and Side Effects
A direct comparison of tirzepatide and semaglutide: mechanism, trial efficacy, side effects, and how to think about choosing between them.
Read the guide → ⚖️ Comparisons & Q&AWhat Does the Research Say About BPC-157 for Gut Health?
A focused look at what research actually supports about BPC-157 for gut health specifically, separate from its broader recovery claims.
Read the guide → ⚖️ Comparisons & Q&AWhat Does the Research Say About Peptides and Longevity?
An honest look at longevity claims made for various peptides, and how thin the human evidence actually is across the category.
Read the guide → ⚖️ Comparisons & Q&AWhat Does the Research Say About Peptides for Athletic Recovery?
An honest overview of what research actually supports across the range of peptides marketed for athletic recovery.
Read the guide →